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Background: Podoconiosis is one of the leading causes of lymphoedema-related morbidity in low-income
settings, but little is known about the scale of its health and economic impact. This information is required
to inform control programme planning and policy. In this study, we estimated the health and economic burden
of podoconiosis in Ethiopia.
Methods: We developed a model to estimate the health burden attributed to podoconiosis in terms of the
number of disability-adjusted life years (DALYs) and the economic burden. We estimated the economic burden
by quantifying the treatment andmorbidity-management costs incurred by the healthcare system inmanaging
clinical cases, patients’ out-of-pocket costs and their productivity costs.
Results: In 2017, there were 1.5 million cases of podoconiosis in Ethiopia, which corresponds to 172073
DALYs or 182 per 100000 people. The total economic burden of podoconiosis in Ethiopia is estimated to be
US$213.2 million annually and 91.1% of this resulted from productivity costs. The average economic burden per
podoconiosis case was US$136.9.
Conclusions: The national cost of podoconiosis is formidable. If controlmeasures are scaled up and themorbidity
burden reduced, this will lead to Ethiopia saving millions of dollars. Our estimates provide important benchmark
economic costs to programme planners, policymakers and donors for resource allocation and priority setting.
Keywords: burden, cost, economic, lymphoedema, podoconiosis
Introduction
Podoconiosis is a non-infectious geochemical disease that causes
massive swelling of the lower leg,1,2 with an estimated 4 million
cases in 32 countries.3 The disease is caused by long-term expo-
sure to soils and thrives in tropical highland areas in genetically
susceptible people who do not use footwear. The disease is a
disabling neglected tropical disease (NTD) and is associated
with profound stigma,4 discrimination5 and comorbid mental
health conditions.6 It is the principal cause of lymphoedema in
Ethiopia7,8; the country bears the highest burden of podoconiosis
globally, with an estimated 35 million people at risk and
1.5 million cases across 345 districts.9,10 Poor awareness of
the condition, weak integration of podoconiosis interventions
with primary healthcare delivery, inadequate donor support
and resource allocation and scant evidence of the health and
economic burden have contributed to the continued burden of
podoconiosis in the country.
Podoconiosis is a development challenge in endemic coun-
tries. In addition to its health consequences, podoconiosis
imposes significant economic burdens on individuals and
households through treatment costs and reduced productivity.11
A previous study established the association between household
food insecurity and presence of podoconiosis.12 Podoconiosis is
highly prevalent in the central highlands of Ethiopia, which are
inhabited by agrarian communities, and so potentially affects
the agricultural productivity of the country.9
The effectiveness of podoconiosis interventions have been
documented. Podoconiosis is preventable through consistent
use of footwear and foot hygiene.13 The WHO recommends
the following basic package of care for patients: treatment
for episodes of adenolymphangitis (ADL) and management of
lymphoedema to prevent episodes of ADL and progression of
disease.13 Previous studies have documented the effectiveness of
this WHO-recommended hygiene-based management,14 which
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reduces the frequency of episodes of ADL and improves quality
of life.15,16 Nonetheless, according to data from 2017, in Ethiopia
only 12% of endemic districts and 3% of total cases had access
to services.17,18 To achieve the goal of treatment coverage, it is
critical to address the cost barriers to patients.
Despite posing a significant health and economic burden
among patients, the overall health and economic burden of
podoconiosis in endemic countries is largely unknown, even
among high burden countries.13 For greater understanding of
the podoconiosis burden and to make the case for investment,
alternative financing mechanisms and to scale up interventions,
it is important that public health policymakers, programme
planners and implementers are provided with robust estimates
of the health and economic burden of podoconiosis. While
previous efforts to estimate the health burden have focused on
the number of podoconiosis cases, no studies have estimated its
burden in terms of disability-adjusted life years (DALYs).9,19 Efforts
to estimate the economic burden of podoconiosis have been
limited to specific localised endemic areas at the subnational
level11,20 and national level estimates are not available.
The main objective of this study was, therefore, to estimate
the health and economic burden of podoconiosis in Ethiopia.
Materials and methods
Building on previous methods successfully applied to estimate
the health and economic burden of lymphatic filariasis (LF),21,22
we developed a model to estimate the health and economic
burden of podoconiosis in Ethiopia. Our model incorporated up-
to-date data from a variety of sources21,23–26 and all costs were
adjusted for inflation to 2017 prices.27,28
A database was created based on data extracted from
numerous online sources.24,25,29 These data sources were used
in previous analyses.21,22. These analyses were conducted using
Microsoft Excel (Microsoft, Seattle, USA).
Epidemiology of podoconiosis in Ethiopia
To estimate the health and economic burden of podoconiosis, it is
critical to know the number of cases and the associated disease
sequelae. To establish this we used the previously published
estimation (developed using geostatisticalmethods) of 1537963
podoconiosis cases in Ethiopia in 2017 (uncertainty interval [UI],
290923–4577031).9 We extracted data from previous studies
and found that of those with podoconiosis, 94%may experience
ADL episodes,30–33 with an average incidence of 5.6 episodes per
year (Table 1).15,30–33
Health burden
The health burden of podoconiosis was measured in DALYs with
one DALY equating to one healthy year of life lost. A DALYs is
a sum of the years of life lost due to premature mortality and
the years lost due to disability (YLD) for people with the health
condition or its consequences. Due to an absence of data, no
excessmortality due to podoconiosis was assumed in the current
analysis. DALYs were calculated based on the YLD for two types
of morbidities: lymphoedema and ADL episodes. Podoconiosis
and LF have similar morbidities in terms of lymphoedema and
ADL episodes. Therefore, the disability weightings were based on
those used for LF within the Global Burden of Disease (GBD) 2017
Study (Table 1). To account for disability during ADL episodes,
we considered an average duration of 4.4 d with a frequency of
5.6 times per annum per patient15,30–33 and a disability weight
of 0.051 (UI: 0.032–0.074).(34) For lymphoedema we used a
disability weight of 0.109 (UI: 0.073–0.154).34,35 Based on the
methodology employed since the GBD 2010 study, we did not
apply a discount rate or age weighting to the DALY estimates.36,37
Since lymphoedema and ADL episodes will coexist, we have
accounted for the overlap in our estimation of burden by using
the multiplicative adjustment method.35,38
Economic burden
The annual economic burden was calculated accounting for the
productivity costs associated with podoconiosis morbidity, the
costs for patients accessingmorbidity-management services and
the costs related to patients seeking treatment without access to
morbidity-management services. Cost datawere standardised to
2017 US$ prices and when necessary adjusted for inflation using
gross domestic product (GDP) deflators.27,28
Productivity costs associated with podoconiosis
morbidity
The estimated reduction in productivity for lymphoedema and
acute episodes associatedwith podoconiosis was based on previ-
ous studies on podoconiosis and LF (Table 1).39 When quantifying
the total number of days with reduced productivity per year,
it was assumed that podoconiosis cases would be potentially
economically active for 300 d per year, 8 h per day (Appendix,
Table S5). This approach does not differentiate between lost paid
or unpaid work (e.g. economic activity can include time spent
on household chores or subsistence farming).21 Potential double
counting of the productive losses from comorbid lymphoedema
and ADL episodes was accounted for.
The productivity costs were quantified using the same
approach as a recent study on the economic burden of LF.21
The human capital approach was used whereby all potential
production not performed by a person because of morbidity or
early mortality is counted as production loss.40 The estimated
number of lost productive days were valued based on the GDP
per capita of the lowest income quintile (as used by Redekop
et al.)41 For Ethiopia this was equivalent to US$0.84 per
productive day (Table 1).
Costs relating to the patients accessing
morbidity-management services
A proportion of patients access formal morbidity-management
services specialised to treat morbidities related to lymphoedema
based on WHO-recommended packages of care. Based on
reports from implementing partners and health management
information data, it is estimated that 25000 patients are treated
annually. The treatment components include cleaning of limbs
with diluted antiseptic solutions, soap and water, bandaging, the
application of emollient to the skin and provision of shoes for
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Table 1. Model parameters and the ranges used within the sensitivity analyses
Parameter Point
estimate
Min. Max. Sources
Epidemiological model
Number of cases 1537963 290923 4577031 9
Number treated annually with morbidity-management services 25000 15000 50000 17
Proportion of podoconiosis cases who experience at least one ADL episode 94% 77 98 19–22
Annual incidence of ADL episodes (per those who experience ALD episodes per year) 5.6 5.5 23.3 19–23
Average duration of an ADL episode (d) 4.4 3 6.4 19–23
Productivity costs associated with podoconiosis morbidity
Reductions in productivity
During an ADL episode 77.5% 72.5% 84.5% 24
With lymphoedema 45.0% 29.0% 83.0% 11
Economic value of a lost productive day
GDP per capita of the lowest income quintile US$0.84 US$0.42 US$1.27 25
Health burden
DALY disability weights
ADL disability weight 0.051 0.032 0.074 26
Lymphoedema disability weight 0.109 0.073 0.154 26
Costs related to patients seeking treatment without access to morbidity-management services
Cost per visit: chronic patients
Public facility: health system (US$) 0.58 0.47 0.70 27
Public facility: patient (US$) 0.51 0.41 0.61 28–30
Private facility (US$) 1.28 1.02 1.53 28–30
Self-treatment (US$) 0.64 0.51 0.77 28–30
Cost per visit: ADL patients
Public facility: health system (US$) 0.58 0.47 0.70 27
Public facility: patient (US$) 1.79 1.43 2.15 28–30
Private facility (US$) 3.47 2.77 4.16 28–30
Self-treatment (US$) 0.64 0.51 0.77 28–30
Costs for patients accessing morbidity-management services
Patients direct treatment cost per year (US$)∗ 22.01 17.61 26.41 31
Patients direct non-medical cost per year (US$)∗ 26.3 21.04 31.56 11
Health system cost per year (US$)∗ 7.91 6.33 9.49 11
Abbreviations: ADL, adenolymphangitis; DALY, disability-adjusted life year; GDP, gross domestic product.
∗The original data related to a 3-mo period and was adjusted to an annual value.
Costs are in 2017 US$ prices and when necessary are adjusted for inflation.
selected patients. Each patient visits a health facility four times
over 12 mo to complete their morbidity management.
The direct costs for patients accessingmorbidity-management
serviceswere stratified into three components (Table 1): patients’
direct treatment costs (costs for treatment supplies), patients’
direct non-medical costs (including expenditure on travel,
lodging and food for patients and accompanying persons) and
health system costs. The health system costs were based on
the staff time required to provide the services.11 The costs
were adjusted for inflation to 2017 prices using local inflation
rates.
Based on the current available literature, patients would lose
16 d per year accessing themorbidity-management services and
a proportion would also be escorted by informal caregivers, who
would also incur productivity losses (Appendix Table S5 ). These
were valued as productivity costs using the same method as
outlined for the productivity costs associated with podoconiosis
morbidity.
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Figure 1. Treatment-seeking behaviour of podoconiosis patients. The sources of the parameters are outlined in Table S5.
Costs related to patients seeking treatment without
access to morbidity-management services
Even among patients without access to specialised morbidity-
management services, some seek generic care.32,33 Among these
patients, three treatment-seeking scenarios were assumed:
seeking treatment from public health facilities, from private
facilities or self-treatment/use of traditional healers.21 The
proportion of patients seeking care at public and private facilities
or opting for self-care are summarised in Figure 1.23,33 The costs
of utilising services from a health facility include the cost of
medication, consultation fees and other costs such as travel and
cost to the health system. The costs for these different types of
treatment visits were taken from a similar analysis performed for
LF21 adjusted to 2017 prices (Table 1; US inflation rates were used
as the majority of treatment costs related with medications).
It was assumed that medication would include analgesia
(ibuprofen), antipyretics (paracetamol) and, in the case of ADL,
antibiotics (amoxicillin).42,43 Treatment of ADL episodes was
assumed to be based on the use of these three medications
for 7 d: amoxicillin (500 mg three times a day), paracetamol
(500mg three times a day) and ibuprofen (400mg twice a day).44
Treatment for those with chronic symptoms was assumed to
be the same but without amoxicillin (Figure 1). Those who self-
treat were assumed to incur lower costs, as they do not require
transport, pay consultation fees or receive antibiotics (Table 1,
Figure 1).
There is also a cost to the health system associated with
patients seeking treatment at public health facilities. As with
a similar analysis,21 we assumed this to be equivalent to the
health system cost associated with an outpatient visit to a rural
health facility. We used cost estimates from the WHO-CHOICE
database29 adjusted to 2017 prices using local inflation rates
(Table 1).
Sensitivity analysis
To test changes in economic burden due to variations in
the parameters, we conducted univariate sensitivity analyses.
Ranges of parameter values were obtained from a literature
search and values from previous LF analyses.21 Relevant param-
eters (such as the disability weights and treatment-seeking
behaviour) were grouped together within the sensitivity analyses.
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Table 2. Health burden and lost days in Ethiopia in 2017
Variable Lymphoedema (hundreds) ADL episodes (hundreds) Total (hundreds)
Cases (episodes) 15 379 80958
DALYs 1676 44 1720
Productive days lost 2077237 226905 2304142
Abbreviations: ADL, adenolymphangitis; DALYs, disability-adjusted life years.
Table 3. Breakdown of annual economic burden of podoconiosis by disease sequelae
Variable Lymphoedema
(US$ thousands)
ADL episodes
(US$ thousands)
Total
(US$ thousands)
Productivity costs associated with podoconiosis morbidity 174972 19159 194131 (91.1%)
Costs related to patients seeking treatment without access to
morbidity-management services
1012 16238 17250 (8.1%)
Costs for patients accessing morbidity-management services 1827 - 1827 (0.9%)
Total 177811 (83.4%) 35397 (16.6%) 213208
Abbreviation: ADL, adenolymphangitis.
Costs are in 2017 US$ prices.
Results
Health burden
In 2017, the number of people living with podoconiosis was
estimated to be 1537963 (UI: 290 923–4577031), with an
annual incidence of 8 million ADL episodes among all patients.
This corresponds to 172073DALYs or 182 per 100000 population.
The majority (97.4%) of these DALYs were due to chronic
lymphoedema, while 2.6% were attributable to ADL episodes
(Table 2).
Economic burden
We estimated that in 2017 the annual total economic burden
due to podoconiosis in Ethiopia was US$213.2 million. The
cost related to patients seeking treatment without access to
morbidity-management serviceswas US$17.2million (8.1%), the
cost of patients accessing morbidity-management services was
US$1.8 million (0.9%) and the productivity cost associated with
podoconiosis morbidity was US$194.1 million (91.1%) (Table 3).
We also estimated that there were 230.4 million productive days
lost per year due to podoconiosis, of which 90.2% were due to
chronic illness and 9.8% to acute episodes (Table 2).
The annual costs related to patients seeking treatment
without access to morbidity-management services (consisting
of health system costs and out-of-pocket patient costs) totalled
US$17.25 million; 94.1% of these costs were due to ADL
episodes. By comparison, ADL episodes only accounted for 9.9%
of productivity costs associated with podoconiosis morbidity
(Table 3).
The average weighted annual economic burden per podoco-
niosis case was estimated to be US$136.9, the majority of
which resulted from lost productivity (US$126.2). On average,
the cost related to patients seeking treatment without access
to morbidity-management services was US$11.4 per case
annually. We estimated that the average annual economic
cost of morbidity management and the associated cost per
podoconiosis case treated was US$73.1 (Table 4).
Sensitivity analysis
Applying univariate sensitivity analysis, the economic burden
was most sensitive to the assumed number of cases. The eco-
nomic burden was also sensitive to the proportion of productivity
losses due to lymphoedema and ADL episodes, incidence of ADL
episodes and daily value of time. Parameters reflecting the num-
ber of cases with access to morbidity management, treatment-
seeking behaviours and treatment costs per visit did not have
a notable impact (Figure 2). The total economic burden ranges
between US$26.1 million to US$1.6 billion when the parameters
are minimised and maximised, respectively.
Discussion
On the basis of 1.5 million cases of podoconiosis in Ethiopia, we
estimated that podoconiosis was responsible for close to 172000
DALYs annually. The average economic burden per podoconiosis
case was US$136.9 and 90% of this resulted from productivity
costs. The total economic burden of podoconiosis in Ethiopia is
estimated to be close to US$213.2million annually. The assumed
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Table 4. Average economic burden per podoconiosis case
Cost category Average economic burden per
podoconiosis case
Costs related to patients seeking treatment without access to morbidity-management services US$11.4
Costs for patients accessing morbidity-management services (per case treated) US$73.1
Productivity costs associated with podoconiosis morbidity US$126.2
Total (weighted average) US$136.9
Costs are in 2017 US$ prices.
Figure 2. Tornado plot illustrating the impact of univariate sensitivity analysis on the estimated economic burden of podoconiosis. The parameters
used for the sensitivity analysis are included in Table 1 and Table S5.
number of podoconiosis cases was based on a nationwide map-
ping and robust modelling approach.9,10 This provides a strong
foundation for the estimation of the economic burden of podoco-
niosis in Ethiopia. Our findings demonstrate that podoconiosis
is an important NTD causing significant health and economic
burdens. They reaffirm that podoconiosis is not only an impor-
tant public health problem but also a formidable developmental
challenge for the country.
The average annual cost per patient (US$136.9) is comparable
with figures estimated for LF.21 In the Ethiopian context, the
figure is significant in a country where more than a quarter
of the population live below the international poverty line
(US$1.9 per capita per day)45 and where the poverty level is
higher in rural areas,45 where podoconiosis is most prevalent.
The number of productive days lost due to podoconiosis and
the incidence of ADL per annum are considerable. These all
emphasise the need to scale upmorbidity-management services
for affected individuals. Previous studies have demonstrated
that lymphoedema-related morbidity management significantly
reduces the frequency of acute episodes,15 is likely to be cost-
effective and generate economic benefits.22,46,47. Our estimates
differ from a previous estimate of the cost per patient for
podoconiosis; this difference is due to our approach in calculating
direct and indirect costs.11
Our study also provides the first nationwide burden esti-
mates for podoconiosis. The burden of podoconiosis is possibly
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under-recognised due to misclassification as other diseases.
The national burden of podoconiosis as expressed in DALYs
(172 073) in 2017 is higher than that of trachoma (15 672),
onchocerciasis (40 558) and leishmaniasis (45 900), although
less than schistosomiasis (178 312) and malaria (201 482).35
In Ethiopia in 2017, all NTDs considered in the GBD estimation
caused 547599 DALYs.35 If podoconiosis was included in the GBD
2017 estimation it would have accounted for 24% of the total
NTD DALYs and 0.5% of the total all-cause DALYs in Ethiopia.35
This is the first estimate to quantify the health and eco-
nomic burden of podoconiosis in Ethiopia. The epidemiology of
podoconiosis and the number of podoconiosis cases estimated is
based on nationwide mapping and a robust modelling approach,
both of which provide a strong foundation for the estimation
of the economic burden. We used a study conducted among
podoconiosis patients to estimate economic costs and produc-
tivity loss.11
The economic burden of podoconiosis was US$213.2 million
annually, based on our sensitivity analysis ranging from US$41
million to US$632 million. The variation was largely driven by
the estimated number of podoconiosis cases. Although robust
methodswere applied inmodelling the estimation of cases, there
were wide uncertainty intervals in the estimates due to factors
potentially unaccounted for in the models.9
Limitations
There are some limitations to our estimation. First, in estimat-
ing the health burden of podoconiosis, we only included ADL
and lymphoedema and there are other possible sequelae. These
include permanent joint fixation and comorbid depression,6 but
these are not included because of paucity of data. One study
found that including mental health sequalae in LF DALY burden
estimates resulted in a near doubling of its estimated DALY
burden.48 In addition, we do not have data on long-term disease
outcomes, including excess mortality due to the disease. This
emphasises the need for data on other sequelae and long-term
outcomes of podoconiosis.
Second, estimates of the proportion of patients seeking care
at public and private facilities or opting for self-care are depen-
dent on a single study for ADL33 and are based on the national
household survey.23 Health service utilisation was also estimated
based on a study conducted among the general population.49 We
believe these estimates are reasonably close to the true figure,
but it is important that podoconiosis-specific data are generated
to improve future estimations of the economic burden.
Third, for determining the productivity costs, we only calcu-
lated productivity losses experienced by the patients (with the
exception of the caregivers assisting with morbidity manage-
ment). Nonetheless, it is likely that many economically produc-
tive family members miss work, particularly during ADL episodes,
to care for patients. Therefore, we recommend a comprehensive
community-based survey in a podoconiosis-endemic area to esti-
mate the aforementioned costs and the number of productive
days lost by caregivers and familymembers. Mental health condi-
tions including depression are common among caregivers as well
as patients, but we have not estimated the potential economic
burden associated with higher prevalence of depression among
caregivers.6
In addition, accurately valuing productivity losses for individ-
uals with podoconiosis is difficult and the correct methodology
is debatable.21 In order to be conservative, the GDP per capita
of the lowest income quintile was used in this study (Table 1).
The human capital approach was used to estimate the pro-
ductivity costs. However, it should be noted that the friction
cost approach (which assumes the employer’s perspective for
valuing lost productivity),50 typically results in lower estimates
of productivity costs. There is continued debate within the field
regarding which approach is most appropriate.40 However, in the
context of podoconiosis, the friction cost approach is difficult
to apply, as the majority of those affected are not in formal
employment. It was assumed that otherwise podoconiosis cases
would have been potentially economically active for 300 d per
year, considering both paid and unpaid work.21 We did not explic-
itly value lost leisure time. However, it should be noted that
distinguishing between the lost unpaid work and leisure time can
be challenging.40 Furthermore, although it was also not possible
to present the results disaggregated by gender, it is probable that
women and men face a different economic burden associated
with podoconiosis.
Finally, we estimated the economic burden of podoconiosis at
national level and we did not show inter-regional variation in the
economic burden of podoconiosis because of the lack of region-
specific cost data. Therefore, we recommend future studies to
address this. Based on the available data, we only performed a
univariate sensitivity analysis. However, as more data become
available, future studies should consider a probabilistic sensitivity
analysis.
To fully understand the cost and economic aspect of
podoconiosis interventions, the following studies are recom-
mended. First, most of our costs are dependent on international
databases23–25,29 and other diseases such as LF,21,22 therefore
it is important to conduct studies which collect either cross-
sectional or longitudinal data on costs related to podoconiosis.
It will be important that such studies collect more detailed
data on health-seeking behaviours as well as further economic
and health burden data on individuals who are self-treating.51
Second, our analysis focused only on Ethiopia, and it is important
in future to estimate the health and economic burden of
podoconiosis in multi county settings (if not at the global scale)
as data on the number of cases become available. Third, cost-
effectiveness studies on hygiene-based treatment and other
preventive interventions are critical.52 Previous studies have
demonstrated the effectiveness of the morbidity-management
intervention,15,16 but the cost-effectiveness of the intervention
has not yet been evaluated.
Conclusions
Our estimate of the health and economic burden of podoco-
niosis suggests that considerable health burdens and economic
losses are borne by Ethiopia. Our findings imply that reducing
the podoconiosis burdenwould contribute to poverty reduction in
the country. The Ministry of Health should scale up podoconiosis
morbidity-management interventions within reasonable access
to those living with podoconiosis. Our estimates provide impor-
tant benchmark economic costs for programme planners, poli-
cymakers and donors for resource allocation and priority setting.
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